4-[(2-{[4-(dimethylamino)phenyl]amino}-1-methyl-1H-benzimidazol-5-yl)oxy]-N-(2-piperidin-1-ylethyl)pyridine-2-carboxamide | 611217-64-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[(2-{[4-(dimethylamino)phenyl]amino}-1-methyl-1H-benzimidazol-5-yl)oxy]-N-(2-piperidin-1-ylethyl)pyridine-2-carboxamide
• 英文别名: 4-[2-[4-(dimethylamino)anilino]-1-methylbenzimidazol-5-yl]oxy-N-(2-piperidin-1-ylethyl)pyridine-2-carboxamide
• CAS: 611217-64-2
• 化学式: C₂₉H₃₅N₇O₂
• 分子量: 513.643
• InChiKey: YTCSWRSROQOSIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  87.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
  申请人：Amiri Payman

  公开号：US20070299039A1

  公开（公告）日：2007-12-27

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组合物和抑制人或动物体内Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Compounds which have activity at M1 receptor and their uses in medicine
  申请人：Cooper David Gwyn

  公开号：US20100204272A1

  公开（公告）日：2010-08-12

  Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  本发明提供了化学式(I)的化合物或其盐：其中R4，R5，R6，Q，A，Y和R的定义如说明书中所定义。本发明还揭示了将该化合物用作药物以及制造用于治疗精神障碍，认知障碍和阿尔茨海默病的药物的用途。本发明还揭示了包含该化合物的制药组合物。
• SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Amiri Payman

  公开号：US20100196368A1

  公开（公告）日：2010-08-05

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本发明提供了新的取代苯并唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。新的化合物组成物可以单独使用或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE
  申请人：Amiri Payman

  公开号：US20120288501A1

  公开（公告）日：2012-11-15

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的取代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种额外的药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
  申请人：Cooper David Gwyn

  公开号：US20120316196A1

  公开（公告）日：2012-12-13

  Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  提供化学式(I)的化合物或其盐： 其中R4、R5、R6、Q、A、Y和R的定义如说明书所述。本发明还公开了将该化合物用作药物治疗精神疾病、认知障碍和阿尔茨海默病以及制造药物的用途。本发明还公开了包含该化合物的制药组合物。